Kaiser Permanente study examined of Pfizer– BioNTech COVID-19 vaccine effectiveness against hospitalization, death, and infection as much as 8 months after vaccination.
A Kaiser Permanente study published today (February 14, 2022), in The Lancet Regional Health– Americas found that a person month after a third dosage, the Pfizer-BioNTech COVID-19 vaccine efficiency is higher for avoiding infection and hospitalization than 2 dosages of the vaccine after 1 month.
” When we looked at the effectiveness of the 2 dosages of Pfizer– BioNTech vaccine versus 3 doses, we see a benefit with 3 doses that goes beyond that achieved with 2 doses alone,” stated Sara Y. Tartof, PhD, an epidemiologist with the Kaiser Permanente Southern California Department of Research & & Evaluation and a member of the faculty of the Kaiser Permanente Bernard J. Tyson School of Medicine, both in Pasadena.
This research study evaluated the primary series of 2 doses of the Pfizer-BioNTech COVID-19 vaccination effectiveness against hospitalization, death, and infection as much as 8 months after vaccination, and also assessed the effectiveness of 3 doses of the vaccine up to 3 months after vaccination.
To evaluate effectiveness, this research study evaluated electronic health records of 3.1 million members of Kaiser Permanente in Southern California from December 14, 2020, to December 5, 2021. Throughout the study duration, 197,535 (6.3%) clients were contaminated with SARS-CoV-2, and of those, 15,786 (8%) were admitted to the health center. During the research study period, the primary version was delta, and not omicron.
2-dose vaccine efficiency against infection declined from 85% throughout the very first month after vaccination to 49% approximately 8 months following vaccination.
2-dose vaccine effectiveness versus hospitalization stayed high (90%) throughout the 8 months and did not subside, other than amongst people who were 75 years of age and older, or who had actually compromised body immune systems.
For individuals who were immunocompromised, the protection against hospitalization dropped to 74%, and for those 75 and older, it was 77%.
3-dose vaccine efficiency was 88% versus infection and 97% against hospitalization within the very first 3 months after vaccination.
” What we see from this research study is that the public health impact of a 3rd dose to avoid extreme disease is considerable,” Tartof said. “Importantly, all studies that have actually examined the vaccine efficiency of a 3rd dose– including ours– have actually shown a meaningful enhancement in vaccine efficiency versus a broad series of SARS-CoV-2 results.”
Recommendation: “Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large United States Health System: A Retrospective Cohort Study” by Tartof, Sara Y. and Slezak, Jeff M. and Puzniak, Laura and Hong, Vennis and Frankland, Timothy B. and Ackerson, Bradley K. and Takhar, Harpreet S. and Ogun, Oluwaseye A. and Simmons, Sarah and Zamparo, Joann M. and Gray, Sharon and Valluri, Srinivas R. and Pan, Kaijie and Jodar, Luis and McLaughlin, John M.,14 February 2022, The Lancet Regional Health– Americas.DOI: 10.2139/ ssrn.3989856.